Mostrando 10 resultados de: 10
Publisher
Drug Metabolism and Drug Interactions(3)
Revista de Biologia Tropical(2)
Clinical Pharmacology and Therapeutics(1)
Current Drug Metabolism(1)
Drug Metabolism and Personalized Therapy(1)
Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and pbkp_redicted phenotypes inPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusEvaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
ReviewAbstract: Interindividual differences in response to drug treatments are mainly caused by differences in drugPalabras claves:Cocktail, Cytochrome P450 (CYP), Genotype, Hispanics, PhenotypeAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., Garza-Ocañas L., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., Lares-Asseff I., Lazalde-Ramos B.P., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusEthnic background and CYP2D6 genetic polymorphisms in Costa Ricans
ArticleAbstract: CYP2D6 differences have already been demonstrated within Latin American populations by the CEIBA.FPPalabras claves:Afro-Caribbean, Amerindian, COSTA RICA, CYP2D6, MESTIZO, Poor metabolizers, populations, Ultrarapid metabolizersAutores:Adrián LLerena, Barrantes R., Calzadilla L.R., Céspedes-Garro C., Enrique Terán, Estévez-Carrizo F.E., Grazina M., Jiménez-Arce G., López-López M., María-Eugenia G.N., Moya G.E., Ortiz-López R., Ramírez-Roa R., Rodeiro I., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M.Fuentes:scopusMDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers
ArticleAbstract: Background: P-glycoprotein is an efflux transporter encoded by the multidrug-resistance MDR-1 gene,Palabras claves:MDR-1, P-Glycoprotein, Pharmacokinetic, QuetiapineAutores:Adrián LLerena, Dorado P., Estévez-Carrizo F.E., González-Vacarezza N., Humberto Fariñas, Penãs-Lledó E.M.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusPerception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in latin America
ReviewAbstract: Pharmacogenetics and Pharmacogenomics areas are currently emerging fields focused to manage pharmacoPalabras claves:adverse drug reactions, Biomarkers, Clinical recommendations, Clinical relevance, PharmacogenomicsAutores:Agúndez J.A.G., Andrés López-Cortés, Cáceres D.D., Castañeda-Hernández G., Cayún J.P., Chiurillo M.A., De Guerra D.C., Encina G., Enrique Terán, Eslava-Schmalbach J., Estévez-Carrizo F.E., García-Martin E., Herrera L., Isaza C.A., Lares-Assef I., Laróvere L., Lavanderos M.A., López M.L., Magno L.A., Morales J.E., Quiñones L.A., Redal M.A., Roco A.M., Rodeiro I., Soria N.W.Fuentes:googlescopusPharmacogenetics in Latin American populations: Regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders
Conference ObjectAbstract: Meeting report of the " Second Symposium on Pharmacology of Cytochrome P450 and Transporters " organPalabras claves:Cytochrome p450, Hispanics, Latin America, pharmacogeneticsAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Doredo P., ElisaAlonso M., Enrique Terán, Estévez-Carrizo F.E., Ferrero V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., García-Mesa M., Garza-Ocañas L., González-Naranjo M.E., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., Lares-Asseff I., Lazalde B., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Remírez-Figueredo D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento-Sánchez A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusUse of pharmacogenetics in bioequivalence studies to reduce sample size: An example with mirtazapine and CYP2D6
ArticleAbstract: In bioequivalence studies, intra-individual variability (CV w) is critical in determining sample sizPalabras claves:bioequivalence, Cost, CYP2D6, Genotypes, intra-individual, variabilityAutores:Abad-Santos F., Adrián LLerena, Carcas-Sansuan A., Dorado P., Estévez-Carrizo F.E., González-Vacarezza N., Penãs-Lledó E.M.Fuentes:scopusRelevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population
ArticleAbstract: CYP2C9, CYP2C19 and CYP2D6 metabolize around 40 % of drugs and their genes vary across populations.Palabras claves:Afro-Caribbean, Amerindian, COSTA RICA, CYP2C19, CYP2C9, CYP2D6, Genomic ancestryAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Vázquez T.C.Fuentes:scopusPbkp_redictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen
ReviewAbstract: Bevacizumab was the first molecular-targeted antiangiogenic therapy approved for the treatment of mePalabras claves:Bevacizumab, Biomarker, Cáncer, colorectalAutores:Adrián LLerena, Alonso I., Arroyo G., de Andrés F., Estévez-Carrizo F.E., González-Vacarezza N., Martínez J.Fuentes:scopus